Phreesia, Inc. (PHR) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents strong financial metrics, including consecutive positive net income and increased cash flow, which are positive indicators. The Q&A session highlights a cautious but optimistic outlook, with plans for strategic investments and growth. While some management responses lack clarity, the overall sentiment is positive due to strong cash flow, margin expansion, and growth potential from acquisitions. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Key Financial Performance
Total Revenue $120.3 million, a 13% increase year-over-year. The increase is attributed to the company's growth strategy and improved returns on investment and attach rates of their offerings.
Adjusted EBITDA $29.1 million, an increase of $19 million year-over-year and $7 million quarter-over-quarter. This improvement reflects disciplined execution and focus on operational efficiency.
Adjusted EBITDA Margin 24%, an all-time high, representing an improvement of 5 percentage points quarter-over-quarter and 15 percentage points year-over-year. This reflects operational leverage and efficiency.
Average Healthcare Services Clients (AHSCs) 4,520, an increase of 53 from the prior quarter. This growth aligns with the company's expectations and reflects successful client acquisition efforts.
Total Revenue per AHSC $26,622, up 6% year-over-year. This steady increase is consistent with the company's growth strategy and focus on improving returns on investment.
Net Income $4.3 million, representing the second consecutive quarter of positive net income. This reflects the company's continued momentum in revenue growth and operating leverage.
Cash and Cash Equivalents $106.4 million, compared to $98.3 million in the prior quarter. This increase is due to improved operating cash flow and disciplined financial management.
Operating Cash Flow $15.5 million, up $9.7 million year-over-year. This improvement reflects better working capital management and operational efficiency.
Free Cash Flow $8.8 million, up $7.2 million year-over-year. This reflects the company's focus on generating sustainable cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Provider Financing: Phreesia has expanded into the provider financing market through the acquisition of AccessOne. This solution addresses the issue of rising patient financial responsibility and helps healthcare providers convert patient receivables into predictable cash flow. The financing solutions improve days cash on hand, decrease days outstanding, and enhance patient affordability.
HCP Marketing: Phreesia is extending its offerings to healthcare provider (HCP) marketing, leveraging its existing patient engagement platform. This initiative aims to engage healthcare providers with relevant evidence-based information before patient appointments, creating a new revenue stream and deepening relationships with providers and life sciences clients.
AccessOne Acquisition: Phreesia acquired AccessOne, which manages a portfolio of approximately $450 million. This acquisition is expected to add 80 Average Healthcare Services Clients (AHSCs) annually and contribute to revenue growth.
HCP Digital Marketing Opportunity: Phreesia is positioning itself to participate in a multibillion-dollar HCP digital marketing market by leveraging its existing infrastructure and relationships.
Revenue Growth: Total revenue for Q3 fiscal 2026 was $120.3 million, a 13% year-over-year increase. Revenue per AHSC grew by 6% year-over-year.
Profitability: Adjusted EBITDA reached $29.1 million, a $19 million year-over-year increase, with a record-high adjusted EBITDA margin of 24%.
Cash Flow: Operating cash flow was $15.5 million, up $9.7 million year-over-year. Free cash flow was $8.8 million, up $7.2 million year-over-year.
Long-term Credit Facility: Phreesia plans to refinance or replace the $110 million secured bridge loan used for the AccessOne acquisition with a long-term credit facility.
Fiscal 2027 Outlook: Phreesia expects fiscal 2027 revenue to range between $545 million and $559 million, with adjusted EBITDA between $125 million and $135 million. AHSCs are expected to grow mid-single-digit percentage, and revenue per AHSC is expected to grow double-digit percentage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Provider Financing Risks: The rising patient financial responsibility in the U.S. is leading to more unpaid patient balances and longer payment cycles, creating financial risks for healthcare providers. This increases working capital pressure and financial instability for providers.
AccessOne Acquisition Risks: The acquisition of AccessOne involves financial risks, including the need to refinance or replace a $110 million secured bridge loan with a long-term credit facility. Additionally, the funded model of AccessOne relies on a relationship with PNC Bank, which could pose operational risks if the partnership faces challenges.
Economic and Market Uncertainty: The company’s forward-looking statements highlight risks related to economic uncertainties and market conditions that could impact financial performance and strategic execution.
HCP Marketing Expansion Risks: The expansion into the Health Care Provider (HCP) marketing space involves risks related to execution and competition in a multibillion-dollar market. The success of this initiative depends on leveraging existing relationships and infrastructure effectively.
Revenue Growth and Client Acquisition Risks: The company’s growth strategy relies on increasing revenue per Average Healthcare Services Client (AHSC) and acquiring new clients. Failure to meet these targets could impact financial performance.
Operational and Integration Risks: The integration of AccessOne and other acquisitions into Phreesia’s operations poses risks, including potential challenges in aligning systems, processes, and cultures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for Fiscal 2026: Updated to a range of $479 million to $481 million, including approximately $7.5 million of revenue contribution from AccessOne.
Adjusted EBITDA Outlook for Fiscal 2026: Updated to a range of $99 million to $101 million, reflecting expected contributions from AccessOne and other factors.
Average Healthcare Services Clients (AHSCs) for Fiscal 2026: Updated to approximately 4,515, reflecting the addition of 15 AHSCs from AccessOne.
Revenue per AHSC for Fiscal 2026: Expected to increase compared to fiscal 2025.
Revenue Outlook for Fiscal 2027: Projected to be in the range of $545 million to $559 million, with AccessOne contributing approximately 6.5% of total revenue.
Adjusted EBITDA Outlook for Fiscal 2027: Projected to be in the range of $125 million to $135 million.
AHSC Growth for Fiscal 2027: Expected to grow in the mid-single-digit percentage range.
Revenue per AHSC for Fiscal 2027: Expected to grow at a double-digit percentage rate.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the growth potential for AccessOne over the next couple of years, and how can it be accelerated?
A:The product is not currently suited for the majority of clients and will require work and investment. The company plans to invest in go-to-market strategies over the next few quarters for both new and existing clients. The acquisition is expected to contribute significantly over multiple years, though the 2027 guidance sets a conservative bar.
Q:Can you provide more color on the refinancing or new loan plans?
A:The company is actively looking to replace the bridge loan with a long-term solution and expects to finalize this in the next few months. There is strong demand for financing based on the company's free cash flow and EBITDA.
Q:What is the go-to-market strategy for mid-single-digit AHSC growth next year?
A:The company sees demand for intake and new AI offerings, particularly voice AI workflows. On the Network Solutions side, Patient Connect and newer offerings like post-script engagement and HCP offerings are driving growth.
Q:What is the core organic growth expectation for fiscal 2027, and how does it compare to fiscal 2026?
A:The fiscal 2027 revenue guidance implies 8%-10% core organic growth. Network Solutions is expected to grow the fastest, followed by payment processing and subscription. The company is monetizing new products like post-script engagement and appointment readiness.
Q:What are the drivers and sustainability of the 450 bps margin expansion in the guidance for next year?
A:The company has focused on capital stewardship and balancing growth with margin improvement. G&A is an area for leverage, while investments in sales, marketing, and R&D will continue as long as growth supports it.
Q:What is the status and reception of the new HCP marketing initiative?
A:The initiative has started for select clients, with strong demand observed. The company believes the initiative represents incremental dollars as DTC and HCP budgets are generally separate.
Q:Why was the fiscal 2026 guidance only increased by $3 million despite a $7.5 million contribution from AccessOne?
A:The company is being more measured around Network Solutions due to fluidity in the selling season. The $4.5 million difference is mostly allocated to Network Solutions.
Q:What is the demand and seasonality for AccessOne's funded and unfunded offerings?
A:AccessOne offers flexibility with various funding options to meet client needs. The company expects to learn more about client preferences over time. Seasonality is expected to align with the provider go-to-market strategy, though revenue may show chunkiness.
Q:What is the impact of fluidity in the Network Solutions selling season on fiscal 2026 and 2027?
A:The fluidity is partly due to uncertainties around DTC advertising. The company believes it is well-positioned long-term but is being cautious in the short term. The situation is similar to last year, but with larger numbers.
Q:What are MediFind's competitive advantages and traction?
A:MediFind focuses on connecting the right patients with the right doctors, avoiding paid product placements. Integration with the Phreesia platform has driven significant usage, and the company plans to continue investing in it.
Q:What are the assumptions behind the fiscal 2027 top-line outlook and the mix of AHSC growth versus revenue per AHSC?
A:The guidance includes AccessOne, contributing about 1 point to mid-single-digit AHSC growth. The mix assumes growth in both AHSC count and revenue per AHSC.
Q:What are the thoughts on a share buyback program given current valuation levels?
A:While a share buyback is a consideration, the current priority is retiring debt from the AccessOne acquisition. Investments in growth opportunities are also a focus.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific growth potential and timeline for AccessOne, providing only general statements about investment and expectations. Similarly, the response to the fluidity in the Network Solutions selling season lacked detailed clarity, focusing instead on long-term positioning without addressing immediate impacts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI capability
AccessOne problem
Care Provider
Conference Instructions
Financing payment
HCP activation
HCP appointment
HCP engagement
HCP marketing
Health Care
Hospitals health
Instructions conference
Investor Phreesia
MediFind insight
Officer Relations
People bill
Phreesia loop
Phreesia multibillion
Phreesia year
PhreesiaOnCall voice
Provider HCP
Relations website
Today network
ability health
ability side
acquisition AccessOne
acquisition ability
care provider
cash hand
conference today
day cash
experience
health care
outlook view
provider financing
provider life
relationship
workflow
PHR Transcript
Phreesia, Inc. (PHR) Q1 2027 Earnings Call Transcript
Unknown5-27
The earnings call indicates strong revenue growth and improved gross margins, which are positive signs. However, the guidance for fiscal year 2027 has been revised downwards, which could negatively impact investor sentiment. The company's net loss has decreased, and cash flow has improved, but operating expenses have increased. The lack of discussion on shareholder returns and the absence of clear responses in the Q&A add uncertainty. Given these mixed signals and the company's small-cap status, the stock is likely to remain stable in the near term, resulting in a neutral sentiment.
Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
Positive3-31
The earnings call presented a mixed but generally positive outlook. The company achieved positive GAAP net income for the first time, showing profitability. Despite revenue reductions, the confidence in maintaining EBITDA guidance and ongoing margin expansion is promising. The strategic focus on AI, integration of AccessOne, and growth in Network Solutions and organic payments are positive indicators. While there are concerns about client spending and GLP-1 drugs, the overall sentiment and strategic direction suggest a likely positive stock price movement, especially for a small-cap stock with a market cap of $1.2 billion.
Phreesia, Inc. (PHR) Q3 2026 Earnings Call Transcript
Positive12-8
The earnings call presents strong financial metrics, including consecutive positive net income and increased cash flow, which are positive indicators. The Q&A session highlights a cautious but optimistic outlook, with plans for strategic investments and growth. While some management responses lack clarity, the overall sentiment is positive due to strong cash flow, margin expansion, and growth potential from acquisitions. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Phreesia, Inc. (PHR) Q2 2026 Earnings Call Transcript
Positive9-4
The earnings call summary highlights strong financial metrics, optimistic guidance, and strategic acquisitions like AccessOne, which align with market expansion and product development goals. The Q&A session revealed analyst confidence in AI integration and new product offerings, despite some uncertainty regarding specific revenue details. The company's market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
PHR Slides
PHR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
